TP-317 is under clinical development by Thetis Pharmaceuticals and currently in Phase I for Inflammatory Bowel Disease. According to GlobalData, Phase I drugs for Inflammatory Bowel Disease have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TP-317’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TP-317 overview
TP-317 is under development for the treatment of acute respiratory distress syndrome (ARDS), ulcerative colitis, Crohn's disease, colon cancer, melanoma, non-small cell lung cancer, pancreatic cancer, metastatic colorectal cancer, small cell lung cancer and ovarian cancer. It is administered through oral, subcutaneous and intravenous routes. It is a new molecular entity (NME). The drug candidate is omega-3 and omega-6 metabolite known as specialized pro-resolving mediators (SPMs). The drug candidate is developed based on high-efficiency amino lipid enabled release (HEALER) technology. It act by targeting ChemR23 (chemerin receptor 23).
It was also under development for the treatment of gastrointestinal disorders.
Thetis Pharmaceuticals overview
Thetis Pharmaceuticals is a clinical-stage biopharmaceutical company. It primarily focuses on the development of a first-in-class, oral Resolvin E1 drug (TP-317) for the treatment of mild-to-moderate inflammatory bowel disease (IBD) and solid tumors. The company’s lead compound, TP-317, is a novel small molecule. Thetis Pharmaceuticals’ products are primarily targeted towards patients suffering from mild-to-moderate Crohn’s disease, ulcerative colitis, and advanced solid tumors. The company operates in the US, Europe, Japan, China, Korea, Canada and Australia. Thetis Pharmaceuticals is headquartered in Essex, Connecticut, the US.
For a complete picture of TP-317’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
